GLP-1 Agonist and Respiratory System Complications: A Comprehensive Review
The use of glucagon-like peptide-1 (GLP-1) receptor agonists has revolutionized the management of type 2 diabetes and obesity. However, recent studies have highlighted the potential respiratory system complications associated with the use of these medications. In this article, we will provide a comprehensive review of the GLP-1 agonist and respiratory system complications, including the benefits and risks of these medications.
Background
GLP-1 receptor agonists are a class of injectable medications that improve glycemic control and weight loss in patients with type 2 diabetes. These medications work by slowing gastric emptying, reducing appetite, and increasing feelings of fullness. However, the use of these medications has been associated with various side effects, including respiratory system complications.
Respiratory System Complications
Studies have shown that GLP-1 receptor agonists may lower the risks of lung cancer, pulmonary fibrosis, and respiratory infections. A systematic review of 14 clinical trials found that GLP-1 receptor agonists reduced the risk of respiratory diseases by 14-26% in high-risk patients. Another study found that semaglutide, liraglutide, and dulaglutide reduced the risk of respiratory diseases by 18%, 14%, and 18%, respectively.
Benefits of GLP-1 Agonists
GLP-1 receptor agonists have been shown to provide lung benefits beyond glycemic control, including reduced risks of lung malignancy, pulmonary infection, and chronic obstructive pulmonary disease (COPD) exacerbations. A study found that patients taking GLP-1 receptor agonists had a reduced risk of COPD exacerbations and hospitalizations.
Risks of GLP-1 Agonists
While GLP-1 receptor agonists have been shown to have various benefits, they also carry certain risks, including respiratory system complications. A study found that patients taking GLP-1 receptor agonists had a higher risk of pneumonia and respiratory infections. Another study found that patients taking GLP-1 receptor agonists had a higher risk of respiratory failure and mortality.
Preoperative Use of GLP-1 Agonists
A cohort study found that patients taking GLP-1 receptor agonists before surgery had a reduced risk of postoperative aspiration pneumonia compared to patients not taking these medications. However, another study found that patients taking GLP-1 receptor agonists before surgery had a higher risk of respiratory failure and mortality.
GLP-1 Agonists and Pulmonary Arterial Hypertension
A study found that adults with pulmonary arterial hypertension taking GLP-1 receptor agonists had a significantly lower risk of mortality and respiratory failure compared to patients not taking these medications.
Conclusion
GLP-1 receptor agonists have been shown to have various benefits, including improved glycemic control, weight loss, and reduced risks of respiratory diseases. However, these medications also carry certain risks, including respiratory system complications. Healthcare providers and patients must weigh the benefits and risks of these medications and consider individual patient factors when making treatment decisions.
Recommendations
Regular monitoring and gradual dose escalation can help reduce gallbladder complications associated with GLP-1 receptor agonists. Patients taking these medications should be monitored closely for signs of respiratory system complications, including pneumonia, respiratory infections, and respiratory failure. Healthcare providers should also consider the potential benefits and risks of these medications when making treatment decisions.
References
- Oct 13, 2025: Our findings indicate that GLP-1RAs may lower the risks of lung cancer, pulmonary fibrosis, and respiratory infections, meriting further prospective study.
- Oct 10, 2025: Aims While discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) before esophagogastroduodenoscopy (EGD) is not universally mandated, safety concerns persist.
- Aug 1, 2025: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are antihyperglycemic agents used to control type 2 diabetes mellitus (T2DM).
- Dec 8, 2024: Chronic respiratory disorders are the third leading cause of mortality globally.
- Oct 23, 2025: Adults with pulmonary arterial hypertension using vs. not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure.
